Literature DB >> 11110572

Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up.

P J Gilling1, K M Kennett, M R Fraundorfer.   

Abstract

BACKGROUND AND
PURPOSE: The holmium laser (2140 nm) can be used to ablate, resect, and enucleate the enlarged prostate. The 2-year results of a randomized trial comparing holmium laser resection of the prostate (HoLRP) and transurethral resection (TURP) are presented. PATIENTS AND METHODS: The 120 patients were randomized to either TURP (N = 59) or HoLRP (N = 61). The patients were reviewed at 1, 3, 6, 12, 18, and 24 months postoperatively. Eighty six (72%) of the patients were available for review at the 2-year mark.
RESULTS: At 2 years, there was no significant difference between the two groups in AUA Symptom Score, peak flow rate (Qmax) value, or quality of life score. Adverse events, including reoperations, incontinence, and loss of erectile potency, were also similar.
CONCLUSIONS: The HoLRP and TURP procedures result in similar clinical outcomes at 2 years.

Entities:  

Mesh:

Year:  2000        PMID: 11110572     DOI: 10.1089/end.2000.14.757

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  19 in total

1.  [S2e guideline of the German urologists: Instrumental treatment of benign prostatic hyperplasia].

Authors:  T Bschleipfer; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; K Höfner
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

2.  Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia.

Authors:  John M Hollingsworth; John T Wei
Journal:  Rev Urol       Date:  2006

Review 3.  New laser treatment approaches for benign prostatic hyperplasia.

Authors:  Nathaniel M Fried
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

4.  [Transurethral enucleation of the prostate with the holmium: YAG laser system: how much power is necessary?].

Authors:  J Rassweiler; M Roder; M Schulze; R Muschter
Journal:  Urologe A       Date:  2008-04       Impact factor: 0.639

Review 5.  The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review.

Authors:  Ryan W Frieben; Hao-Cheng Lin; Peter P Hinh; Francesco Berardinelli; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

6.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

Review 7.  Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

Authors:  Matthew Ryan Macey; Mathew C Raynor
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

Review 8.  Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.

Authors:  J E Batista-Miranda; M D Diez; P A Bertrán; H Villavicencio
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

9.  Evolution and success of holmium laser enucleation of the prostate.

Authors:  Amy E Krambeck
Journal:  Indian J Urol       Date:  2010-07

10.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.